Home
About
Technology
Products
R&D Services
Investors
News
Contact
More
17 May 2023
Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement
28 Mar 2023
Gemina Labs announces closing of private placement
27 Mar 2023
Gemina Labs to Host Investor Webinar on March 30, 2023
7 Mar 2023
Gemina Appoints Diagnostic Strategist Martha Najib to the Board
25 Jan 2023
Gemina appoints healthcare industry leader, Dr Bola Grace to the Board of Directors
23 Jan 2023
Top ranked UK analyst and scientist, Dr Stefan Hamill appointed VP for Strategy
10 Jan 2023
Gemina Labs strategic update: Focus on respiratory infections and new strategic partnerships on the horizon
6 Jan 2023
Gemina Labs completes influenza A/B diagnostic test prototype
20 Dec 2022
Gemina appoints Dr Michael Shannon as Chair of Clinical Advisory Board
19 Dec 2022
Gemina announces collaboration on next-generation biosensors
13 Dec 2022
Gemina's recent investment into RAPIvD sees immediate progress
7 Dec 2022
Announcement of strategic stake in UK-based rapid test optimizer, RAPIvD
6 Oct 2022
Gemina enters into license and manufacturing agreements
12 Sept 2022
Gemina presents at the H.C. Wainwright Global Investment Conference
6 Sept 2022
Diagnostic executive, Brian Firth, appointed as CEO
11 Jul 2022
Closing of concurrent private placement announced
30 Jun 2022
Closing of prospectus supplement offering and update to concurrent non-brokered private placement
24 Jun 2022
Filing of prospectus supplement
21 Jun 2022
Gemina announces proposed financing up to $5 million
8 Jun 2022
Point-of-care diagnostic executive, Brian Firth, appointed as advisor
17 May 2022
CE Mark for first product – the best-in-class LEGIO-X COVID test
5 May 2022
Successful human clinical performance evaluation on LEGIO X COVID-19 TEST
28 Apr 2022
Phase 2 human patient testing for initial diagnostic test nears completion
31 Mar 2022
Technical development update for initial diagnostic test and filing of new IP
23 Feb 2022
Gemina establishes UK subsidiary and appoints David Browning as Head of Productization
15 Feb 2022
Strategic Update: From platform to product. Gemina provides a technology roadmap
3 Feb 2022
Gemina Labs announces completion of significant development step for its SARS-COV-2 rapid test
18 Nov 2021
Gemina Labs appoints Mike Catt as Senior Scientific Adviser
25 Oct 2021
Gemina Labs announces closing of oversubscribed private placement
20 Oct 2021
Gemina Labs announces private placement
20 Sept 2021
Positive initial manufacturing results for Covid diagnostic test
13 Sept 2021
Update on R&D activities, company milestones and corporate development initiatives
30 Aug 2021
Gemina expands development competencies with three new appointments
10 Aug 2021
Gemina Labs is pleased to announce that the common shares of the Company have begun trading on the Canadian Securities Exchange